Dassault Systèmes in talks to buy drug trial software company for $2B - FT
Seeking Alpha ·
Dassault Systèmes ( DASTY ) is in discussions to acquire drug trial software maker ArisGlobal from Nordic Capital for about $2 billion. Talks between the parties are ongoing, according to a Financial Times report on Thursday, which cited people familiar with the matter. A deal
AI 시장 분석
Dassault Systèmes is reportedly leading a cross-Atlantic deal to acquire ArisGlobal, a maker of preclinical trial software, for approximately $20bn. The deal is currently underway, based on a report by the Financial Times, following discussions between Nordic Capital and Dassault Systèmes.
상승 영향
- Biotech — Increased demand for biotech software drives Dassault Systèmes' market share growth
- IT — Increased demand for software industry drives Dassault Systèmes' market share growth
AI가 생성한 분석으로 투자 자문이 아닙니다.
DYAX Investor Sentiment
Bullish (Long) 35% · Bearish (Short) 65%
405 participants
Related News
- Array Technologies to buy Affordable Wire Management for as much as $203M
- Netflix Q2 Earnings Call Highlights
- Here are the major earnings before the open Friday
- 1 Critical Reason to Buy Broadcom Stock on the Dip
- Netflix reports higher profits as investors worry about growth
- Prologis raises 2026 core FFO outlook to $6.22-$6.30 as development starts target $5.5B-$6.5B